Beranda › Kanker Paru › Pennsylvania › Erie
Uji klinis Kanker Paru di Erie, PA
4 studi untuk Kanker Paru mencari peserta di lokasi sekitar Erie (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Menerima pesertaFase 3
- UPMC Hillman Cancer Center Erie, Erie
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
Menerima pesertaFase 3
- UPMC Hillman Cancer Center Erie, Erie
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
Menerima pesertaFase 2
- UPMC Hillman Cancer Center Erie, Erie
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Menerima pesertaFase 2/3
- UPMC Hillman Cancer Center Erie, Erie
Uji klinis Kanker Paru di kota lain
- Houston, TX78 studi
- Boston, MA62 studi
- New York City, NY60 studi
- Los Angeles, CA45 studi
- Arlington, VA41 studi
- Washington, DC41 studi
- Chicago, IL41 studi
- Baltimore, MD40 studi
- Nashville, TN40 studi
- St. Louis, MO39 studi
- Columbus, OH37 studi
- Philadelphia, PA36 studi
Studi lain di Erie
- Degenerasi Makula10 studi
- Karsinoma Sel Skuamosa Kepala dan Leher6 studi
- Kanker Prostat5 studi
- Kanker Paru Non-Sel Kecil5 studi
- Kanker Mulut5 studi
- Atrofi Geografis5 studi
- Kanker Laring4 studi
- Kanker Ginjal (Karsinoma Sel Renal)4 studi
- Kanker Payudara3 studi
- Ambliopia3 studi
- Kanker Endometrium3 studi
- Kanker Hipofaring3 studi
Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.